Recursion Pharmaceuticals (RXRX)
(Delayed Data from NSDQ)
$5.89 USD
+0.36 (6.51%)
Updated Oct 14, 2025 04:00 PM ET
After-Market: $5.88 -0.01 (-0.17%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
RXRX 5.89 +0.36(6.51%)
Will RXRX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for RXRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RXRX
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know
Recursion Pharmaceuticals (RXRX) Surges 8.2%: Is This an Indication of Further Gains?
RXRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why
Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know
RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
Other News for RXRX
Is RXRX building bullish momentum? Non-ADX 1,2,3,4 Bullish shows up after climbing 3.95%
Recursion Pharmaceuticals call volume above normal and directionally bullish
Recursion Pharmaceuticals call volume above normal and directionally bullish
Is RXRX setting up for a drop? Fell Below 200 Day Moving Average shows up after tumbling 9.98%
200 Day Moving Average Support appears for RXRX after 2.96% move